To explore the CD30 potency as a target, clinical trials at the recruiting stage are ongoing to explore anti-CD30 CAR-T cells as a therapy to treat AITL patients and other T-cell lymphomas and leukemia (NCT04008394). The gene discussed is TNFRSF8; the disease is angioimmunoblastic T-cell lymphoma.